RJFSA
VKTX icon

Raymond James Financial Services Advisors’s Viking Therapeutics VKTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$26.3K Buy
+500
New +$29.3K ﹤0.01% 3387

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Raymond James Financial Services Advisors's VKTX Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Viking Therapeutics (VKTX) stake by 34% in Q3 2024, buying an estimated $1.96M and bringing the position to 130,306 shares worth $8.25M. The position accounts for 0.01% of the portfolio, ranked #961.

Raymond James Financial Services Advisors first reported a position in VKTX in Q4 2018 and has held it in 24 quarters since. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Raymond James Financial Services Advisors held 130,306 shares of Viking Therapeutics worth $8.25M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 33,401 Viking Therapeutics shares in Q3 2024, an estimated $1.96M.
  • Viking Therapeutics made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #961 holding.
  • Raymond James Financial Services Advisors first reported a position in Viking Therapeutics in Q4 2018 and has held it in 24 quarters since.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.